23:08 , Nov 28, 2018 |  BC Innovations  |  Emerging Company Profile

Cybrexa: pH-based tumor targeting

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors. Cybrexa...
21:15 , Sep 28, 2018 |  BioCentury  |  Finance

Activating Akrevia

Akrevia Therapeutics LLC parlayed preclinical proof-of-concept data from its tumor-activated therapies into a $30 million series A round co-led by Atlas Venture and F-Prime Capital Partners. Akrevia, which emerged from stealth on Sept. 27, uses...
17:56 , Sep 28, 2018 |  BC Week In Review  |  Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched on Sept. 27 with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture. Akrevia’s Aklusion platform enables biological molecules such as antibodies,...
15:37 , Sep 27, 2018 |  BC Extra  |  Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture. Akrevia’s Aklusion platform enables biological molecules such as antibodies, cytokines and chemokines...